The Effect of Preoperative Duloxetine on the Occurance of Postoperative Delirium in Patients Undergoing Cancer Surgery.
Launched by AMIRA HASSAN AHMED ALI · Jul 10, 2023
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether taking a medication called duloxetine before cancer surgery can help reduce the chances of patients experiencing postoperative delirium, which is a serious condition that can cause confusion and changes in mental status after surgery. The trial will involve adult patients who are preparing for surgery to treat cancer, and it aims to find out if duloxetine can make a difference.
To participate, patients need to be adults who are healthy enough for surgery and can understand the study, as they will need to provide consent. However, individuals with certain conditions, such as existing cognitive issues or severe mental health problems, will not be eligible. This trial is not yet recruiting participants, but once it begins, those who qualify will be given either duloxetine or a placebo (a harmless pill with no active medication) before their surgery. The goal is to see if taking duloxetine helps them recover better and avoids confusion afterward.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients will sign an informed consent prior to inclusion in the study.
- • Adult patients with ASA class I-III, undergoing cancer surgery.
- Exclusion Criteria:
- • Patients with pre-existing neuro- cognitive dysfunction.
- • Documented signs of dementia after psychiatric evaluations.
- • Language barriers or deafness.
- • Psychosis stroke, meningitis, or brain tumors
About Amira Hassan Ahmed Ali
Amira Hassan Ahmed Ali is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative clinical studies. With a strong focus on ethical standards and regulatory compliance, Amira oversees the design, implementation, and management of clinical trials across various therapeutic areas. Her expertise in project management and collaboration with multidisciplinary teams ensures the successful execution of trials, fostering an environment of scientific rigor and integrity. Through her leadership, Amira aims to contribute significantly to the development of new treatments and therapies that enhance the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Assiut, , Egypt
Patients applied
Trial Officials
Amira Hassan Ahmed, resident
Principal Investigator
Faculty of medecine,assiut,Egypt
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported